While an adverse event reported in Intellia’s gene therapy trial was a “non-concern” for analysts, it follows a handful of patient deaths in other trials for the modality and sent the company’s stock ...

Looking for a biopharma job in New York? Check out the BioSpace list of seven companies hiring life sciences professionals ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

Teos expects to absorb nearly $25 million in one-time costs for severance and termination payments. The biotech had 173 ...

In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, ...

It’s called the peak-end rule. People remember two things most about an experience: the most emotionally intense moment and ...

The canceled contract comes as Moderna nears a critical FDA decision for its next-generation COVID-19 vaccine.

Nearly a third of employed and almost half of unemployed BioSpace survey respondents are seriously considering leaving the ...

Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...

A February executive order on pharmaceutical price transparency does nothing to change the incentives that keep costs opaque. But drug companies and other stakeholders would reap the benefits of such ...

InflaRx’s vilobelimab met the bar for futility in a Phase III trial for the rare skin disease pyoderma gangrenosum.

HHS Secretary RFK Jr. removes the COVID-19 vaccine recommendation for healthy kids and pregnant women—the latest in a string of changes to vaccine policies; judge issues an order to halt HHS’ ...